LIVIVO - The Search Portal for Life Sciences

zur deutschen Oberfläche wechseln
Advanced search

Search results

Result 1 - 2 of total 2

Search options

  1. Article ; Online: Opioid-prescribing considerations in patients with cancer and substance misuse or substance use disorder: a scoping review protocol.

    Jones, Katie Fitzgerald / Malinowski, Jennifer / Paice, Judith / Childers, Julie / Bulls, Hailey W / Morrison, Jeni / Ho, J Janet / Alsbrook, Karen / Nugent, Shannon / Broglio, Kathleen / Nickels, Katrina / Holbein, Monika / Parajuli, Jyotsana / Merlin, Jessica S

    JBI evidence synthesis

    2023  Volume 21, Issue 4, Page(s) 812–825

    Abstract: Objective: This scoping review aims to describe factors in the existing literature that may inform opioid-prescribing decisions for patients with a past or present history of cancer and past or present substance misuse or substance use disorder.: ... ...

    Abstract Objective: This scoping review aims to describe factors in the existing literature that may inform opioid-prescribing decisions for patients with a past or present history of cancer and past or present substance misuse or substance use disorder.
    Introduction: Opioids and opioid-related decisions are critical components of cancer care. Most individuals with cancer will experience pain during cancer care, and over half of patients will receive an opioid prescription. Opioid-prescribing decisions require weighing the benefits and harms. The presence of substance misuse or substance use disorder may elevate the risk of opioid-related harms, but there is a lack of consensus on managing patients at this intersection.
    Inclusion criteria: This review will consider studies that include adult patients with a past or present history of cancer who also have pain and current or historical substance misuse or substance use disorder. The pain may be cancer-related or non-cancer-related. Studies of patients with all types of cancer will be eligible for inclusion, with the exception of non-melanoma skin cancers. Eligible studies will explore factors that inform opioid-prescribing decisions in this patient population.
    Methods: The review will be conducted according to JBI methodology for scoping reviews. Studies written in English since database inception will be included. The databases to be searched include MEDLINE (Ovid), CINAHL (EBSCO), Embase, APA PsycINFO, and Google Scholar. Eligible studies will undergo data extraction by 2 independent reviewers using a data extraction tool created by the authors. A narrative summary will describe study characteristics, population details, and strategies used to determine appropriate pain management in the patient population.
    MeSH term(s) Adult ; Humans ; Analgesics, Opioid/adverse effects ; Opioid-Related Disorders/drug therapy ; Opioid-Related Disorders/epidemiology ; Pain/drug therapy ; Neoplasms/complications ; Neoplasms/drug therapy ; Neoplasms/epidemiology ; Review Literature as Topic
    Chemical Substances Analgesics, Opioid
    Language English
    Publishing date 2023-04-01
    Publishing country United States
    Document type Journal Article ; Research Support, N.I.H., Extramural ; Research Support, Non-U.S. Gov't
    ISSN 2689-8381
    ISSN (online) 2689-8381
    DOI 10.11124/JBIES-22-00007
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

  2. Article ; Online: Expert consensus-based guidance on approaches to opioid management in individuals with advanced cancer-related pain and nonmedical stimulant use.

    Jones, Katie Fitzgerald / Khodyakov, Dmitry / Han, Benjamin H / Arnold, Robert M / Dao, Emily / Morrison, Jeni / Kapo, Jennifer / Meier, Diane E / Paice, Judith A / Liebschutz, Jane M / Ritchie, Christine S / Merlin, Jessica S / Bulls, Hailey W

    Cancer

    2023  Volume 129, Issue 24, Page(s) 3978–3986

    Abstract: Background: Clinicians treating cancer-related pain with opioids regularly encounter nonmedical stimulant use (i.e., methamphetamine, cocaine), yet there is little evidence-based management guidance. The aim of the study is to identify expert consensus ... ...

    Abstract Background: Clinicians treating cancer-related pain with opioids regularly encounter nonmedical stimulant use (i.e., methamphetamine, cocaine), yet there is little evidence-based management guidance. The aim of the study is to identify expert consensus on opioid management strategies for an individual with advanced cancer and cancer-related pain with nonmedical stimulant use according to prognosis.
    Methods: The authors conducted two modified Delphi panels with palliative care and addiction experts. In Panel A, the patient's prognosis was weeks to months and in Panel B the prognosis was months to years. Experts reviewed, rated, and commented on the case using a 9-point Likert scale from 1 (very inappropriate) to 9 (very appropriate) and explained their responses. The authors applied the three-step analytical approach outlined in the RAND/UCLA to determine consensus and level of clinical appropriateness of management strategies. To better conceptualize the quantitative results, they thematically analyzed and coded participant comments.
    Results: Consensus was achieved for all management strategies. The 120 Experts were mostly women (47 [62%]), White (94 [78%]), and physicians (115 [96%]). For a patient with cancer-related and nonmedical stimulant use, regardless of prognosis, it was deemed appropriate to continue opioids, increase monitoring, and avoid opioid tapering. Buprenorphine/naloxone transition was inappropriate for a patient with a short prognosis and of uncertain appropriateness for a patient with a longer prognosis.
    Conclusion: Study findings provide urgently needed consensus-based guidance for clinicians managing cancer-related pain in the context of stimulant use and highlight a critical need to develop management strategies to address stimulant use disorder in people with cancer.
    Plain language summary: Among palliative care and addiction experts, regardless of prognosis, it was deemed appropriate to continue opioids, increase monitoring, and avoid opioid tapering in the context of cancer-related pain and nonmedical stimulant use. Buprenorphine/naloxone transition as a harm reduction measure was inappropriate for a patient with a short prognosis and of uncertain appropriateness for a patient with a longer prognosis.
    MeSH term(s) Humans ; Female ; Male ; Analgesics, Opioid/adverse effects ; Cancer Pain/drug therapy ; Cancer Pain/etiology ; Consensus ; Buprenorphine/therapeutic use ; Naloxone/therapeutic use ; Neoplasms/complications ; Neoplasms/drug therapy
    Chemical Substances Analgesics, Opioid ; Buprenorphine (40D3SCR4GZ) ; Naloxone (36B82AMQ7N)
    Language English
    Publishing date 2023-09-11
    Publishing country United States
    Document type Journal Article ; Research Support, N.I.H., Extramural ; Research Support, Non-U.S. Gov't
    ZDB-ID 1429-1
    ISSN 1097-0142 ; 0008-543X ; 1934-662X
    ISSN (online) 1097-0142
    ISSN 0008-543X ; 1934-662X
    DOI 10.1002/cncr.34921
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

To top